FISHER & PAYKEL HEALTHCARE C

Fisher & Paykel’s first‑half FY‑2026 results show revenue and earnings growth driven by integrated R&D, manufacturing, and agile supply‑chain expansion, positioning the company to meet full‑year targets amid macro headwinds.

Kingfish Limited spotlights Fisher & Paykel Healthcare, citing 12.5% portfolio weight and 10% revenue growth, as a resilient healthcare win for investors and patients alike.

Fisher & Paykel Healthcare declares a 30% dividend, revealing strong cash flow and growth while backing next‑gen medical devices and patient‑centric care.

Fisher & Paykel Healthcare’s Q4 2025 update shows robust cash, 12% cash‑flow growth, and a 55% margin—fueling R&D, value‑based pricing, and strategic expansion in global healthcare markets.

Fisher & Paykel Healthcare’s latest earnings show steady growth driven by high‑margin respiratory and anaesthesia products, robust pipeline, and tariff‑mitigation strategies.

FPHC director Graham McLean boosts stake to 4,900 shares, underscoring confidence amid rising NAV and active buyback plans—key insights for investors.